1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve...

Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure” SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, has been invited to participate as an...

Sorrento Therapeutics Chairman/CEO update to stockholders SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Dear Sorrento Stockholders, Despite a recent short seller opinion piece aimed at undermining the credibility...

Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it has entered into a securities purchase agreement to sell $120.5 million...

Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento") announced today that it appointed Mr Jiong Shao as Executive Vice President and Chief Financial...